Takeda Pharmaceutical Company Limited and its wholly owned subsidiary, Takeda Pharmaceuticals International GmbH, report that the European Commission has granted marketing authorization for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, to treat ulcerative colitis and Crohn’s disease in adults. FDA approved the drug in May 2014.

Vedolizumab is now approved for marketing in the 28 member states of the European Union as well as Norway, Iceland, and Liechtenstein. The drug was approved by FDA in May 2014.

Source: Takeda Pharmaceutical